UIC Law Student Destinee Burrell Helps Publish Patent Jury Instruction Handbook

Chicago, Illinois, Feb. 03, 2021 (GLOBE NEWSWIRE) — Destinee Burrell, a third-year student at UIC John Marshall Law School in Chicago, was one of three law students in the country who assisted with research and updates for the 2020-21 Patent Jury Instruction Handbook. The Handbook provides a comprehensive sampling of annotated jury instructions used in actual patent infringement actions.

The Handbook has been updated annually since 2015 by Edward D. Manzo of HuschBlackwell LLP, with assistance from George S. Pavlik. It covers the legal issues most often implicated in a patent infringement trial and offers expert commentary for additional guidance. It includes model jury instructions from the American Intellectual Property Law Association, the Federal Circuit Bar Association, the National Jury Instruction Project, the Intellectual Property Organization, the Northern District of California and the Seventh Circuit.

Burrell got involved with the project during her time as a summer associate at HuschBlackwell. Her role in the project included checking for updated model instructions; looking for the biggest patent jury cases and jury awards through annual wrap-up review articles; and conducting an advanced search on Westlaw for patent cases with jury instructions within the last year.

While working on The Handbook, Burrell says she relied heavily on the skills she learned from her Lawyering Skills professors at UIC Law. “Professor Wojcik was my Lawyering Skills I professor, and he was very influential and helpful in the development of my writing skills,” Burrell said. “Almost two years later, he still makes himself available to past students in any way he can.”

UIC Law’s Lawyering Skills Program is ranked among the nation’s best by U.S. News & World Report. The Program, currently ranked #7 in the nation, has continuously been in the top ten since the rankings began. It is known for its rigorous research and writing requirements and its robust faculty leadership. 

During her law school career, Burrell served as Secretary and currently serves as Vice President for the Black Law Students Association. She is an Associate Justice for the Moot Court Honors Program and served as a teaching assistant for two semesters for Lawyering Skills courses.

Amidst a busy schedule, Burrell still finds time to volunteer. She serves as a board member for the South Shore Neighborhood Alliance organization, whose mission is to reestablish neighborly values, unify community organizations and increase families’ awareness of resources in the South Shore Community. She also works with Bronzeville Cares, an organization that provides relief for one of Chicago’s most historic and vulnerable communities. 

In addition to gaining practical training experience as a summer associate at HuschBlackwell, Burrell also participated in the Law School’s Trademark Clinic and completed a judicial externship with the United States District Court for the Northern District of Illinois. After graduation, she will join HuschBlackwell as an associate, practicing in the commercial ligation group.

About UIC John Marshall Law School

UIC Law is the 16th college at the University of Illinois at Chicago—Chicago’s largest university and its only public Carnegie Research 1 institution. Located in the heart of the City’s legal, financial and commercial districts, UIC Law is recognized as one of the most diverse law schools in the nation and is a leader in providing access to underrepresented students.



Miller McDonald
UIC John Marshall Law School
[email protected]

Endeavour Announces Receipt of Final Approvals for Teranga Transaction

ENDEAVOUR ANNOUNCES RECEIPT OF FINAL APPROVALS FOR TERANGA TRANSACTION

George Town, February 3, 2021 – Endeavour Mining (“Endeavour”) (TSX: EDV) (OTCQX: EDVMF) is pleased to announce that it has received all of the regulatory approvals required for its acquisition of Teranga Gold Corporation (“Teranga”) (TSX:TGZ; OTCQX:TGCDF), as announced on November 16, 2020. As such, Endeavour expects to close the acquisition on or around February 8, 2021.

Endeavour received written confirmation from the Minister of Innovation, Science and Industry stating that the acquisition has been approved under the Investment Canada Act, thereby satisfying the applicable condition in the Arrangement Agreement (the “Arrangement”). In addition, Teranga received the final order from the Ontario Superior Court on January 29, 2021, approving the plan of arrangement.

The previously announced La Mancha investment of US$200 million is expected to close during the quarter. The investment will be made at the previously set price of C$29.36 per share, which represents an 8% premium to yesterday’s closing price.

Further details regarding the Arrangement can be found in the joint management information circular of Endeavour and Teranga dated December 17, 2020 available on SEDAR under Endeavour’s profile at www.sedar.com.  

CONTACT
INFORMATION

Martino De Ciccio

VP – Strategy & Investor Relations
+44 203 640 8665
[email protected]

Brunswick Group LLP in London

Carole Cable, Partner
+44 7974 982 458
[email protected]

 

Vincic Advisors in Toronto

John Vincic, Principal

+1 (647) 402 6375
[email protected]

The Toronto Stock Exchange has neither reviewed nor accepts responsibility for the adequacy or accuracy of this news release.

ABOUT ENDEAVOUR
MINING
CORPORATION

Endeavour Mining is a multi-asset gold producer focused on West Africa, with two mines (Ity and Agbaou) in Côte d’Ivoire, four mines (Houndé, Mana, Karma and Boungou) in Burkina Faso, four potential development projects (Fetekro, Kalana, Bantou and Nabanga) and a strong portfolio of exploration assets on the highly prospective Birimian Greenstone Belt across Burkina Faso, Côte d’Ivoire, Mali and Guinea.   

As a leading gold producer, Endeavour Mining is committed to principles of responsible mining and delivering sustainable value to its employees, stakeholders and the communities where it operates. Endeavour is listed on the Toronto Stock Exchange, under the symbol EDV.

For more information, please visit


www.endeavourmining.com


.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Endeavour with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding the delisting of the common shares of Teranga and the application of Teranga to cease to be a reporting issuer. 

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect Endeavour management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Endeavour believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. This forward-looking information may be affected by risks and uncertainties in the combined business of Endeavour and market conditions. This information is qualified in its entirety by cautionary statements and risk factor disclosure contained in filings made by Endeavour with the Canadian securities regulators, including Endeavour’s annual information form, financial statements and related MD&A for the financial year ended December 31, 2019 filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Endeavour has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Endeavour does not intend, and do not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Attachment



IRTC DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against iRhythm Technologies, Inc.– IRTC

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) — Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of iRhythm Technologies, Inc. (NASDAQ: IRTC) from August 4, 2020 through January 28, 2021, inclusive (the “Class Period”). The lawsuit seeks to recover damages for iRhythm Technologies, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: iRhythm’s business would suffer as a result of the U.S. Centers for Medicare and Medicaid Services’ (“CMS”) rulemaking; reimbursement rates would in fact plummet; a lack of national pricing in the CMS rule and fee schedule would cause uncertainty and weakness in the Company’s business; and as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than April 2, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:
Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1410
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
[email protected]



XOM DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Exxon Mobil Corporation– XOM

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) — Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Exxon Mobil Corporation (NYSE: XOM) from November 6, 2019 through January 14, 2021, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Exxon Mobil Corporation investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit,  defendants made false and/or misleading statements and/or failed to disclose that: Exxon forced its employees to use unrealistic assumptions regarding the timelines for well drilling in the Permian Basin; the foregoing assumptions served to artificially inflate the value of the Company’s well operations in the Permian Basin; the foregoing conduct, when revealed, subjected Exxon to a heightened risk of regulatory investigation and oversight; and as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than March 29, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  



CLSK DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against CleanSpark, Inc.– CLSK

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) — Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of CleanSpark, Inc. (NASDAQ: CLSK) from December 31, 2020 through January 14, 2021, inclusive (the “Class Period”). The lawsuit seeks to recover damages for CleanSpark, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: the Company had overstated its customer and contract figures; several of the Company’s recent acquisitions involved undisclosed related party transactions; and as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

 



VYGR DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Voyager Therapeutics, Inc.– VYGR

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) — Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) from June 1, 2017 through November 9, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Voyager Therapeutics, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit,  defendants made false and/or misleading statements and/or failed to disclose that: the Company’s VY-HTT01 IND submission to the FDA lacked key information regarding certain chemistry, manufacturing and controls (“CMC”) matters, including, inter alia, drug-device compatibility and drug substance and product characterization; the Company’s IND submission for VY-HTT01 was therefore deficient; the Company had thus materially overstated the likelihood of FDA approval for VY-HTT01 based on the IND submission; and as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you wish to serve as lead plaintiff, you must move the Court no later than March 24, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  



BTBT DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Bit Digital, Inc.– BTBT

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Bit Digital, Inc. (NASDAQ: BTBT) from December 21, 2020 through January 8, 2021, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Bit Digital, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit,  defendants made false and/or misleading statements and/or failed to disclose that: Bit Digital overstated the extent of its a bitcoin mining operation; as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  



WMT DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Walmart Inc.– WMT

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) — Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of  Walmart Inc. (NYSE: WMT) from March 30, 2016 through December 22, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Walmart Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit,  defendants made false and/or misleading statements and/or failed to disclose that: the Company knowingly filled prescriptions that were issued by so-called “pill-mill” prescribers; the Company filled thousands of prescriptions that showed obvious red flags, including highly-dangerous cocktails of drugs; the Company’s managers made it difficult for Walmart pharmacists to comply with their legal obligations by pressuring them to fulfill as many orders as possible; hence, the Company’s pharmacy revenues were inflated because the Company filled thousands of invalid prescriptions in violation of the Controlled Substance Act dispensing requirements; the aforementioned conduct would subject the Company to regulatory scrutiny; and as a result, Defendants’ statements about Walmart’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  



Healthcare Trust of America, Inc. Sets Dates to Report 2020 Fourth Quarter Financial Results and Host Conference Call

PR Newswire

SCOTTSDALE, Ariz., Feb. 3, 2021 /PRNewswire/ — Healthcare Trust of America, Inc. (NYSE:HTA), the largest dedicated owner and operator of medical office buildings in the United States, announced today that on Monday, February 22nd, 2021, after the market closes, HTA will report its financial results for the three months ending December 31st , 2020. 

The Company plans to host a conference call and webcast on Tuesday, February 23rd, 2021 at 12:00 p.m. Eastern Time to review its financial performance and operating results for the three months ending December 31, 2020.

Conference Call and Webcast:
Domestic: (877) 507-6265 / International: (412) 902-6633 / Canada: (855) 669-9657
Webcast: www.htareit.com under the Investor Relations tab

Replay:
Domestic: (877) 344-7529 / International: (412) 317-0088 / Canada: (855) 669-9658
Conference ID: 10152006
Available February 23rd, 2021 (one hour after the end of the conference call) to March 23rd, 2021 at 12:00 p.m. Eastern Time

About HTA
Healthcare Trust of America, Inc. (NYSE: HTA) is the largest dedicated owner and operator of medical office buildings in the United States, comprising approximately 25.1 million square feet of GLA, with $7.4 billion invested primarily in medical office buildings as of September 30, 2020.  HTA provides real estate infrastructure for the integrated delivery of healthcare services in highly-desirable locations.  Investments are targeted to build critical mass in 20 to 25 leading gateway markets that generally have leading university and medical institutions, which translates to superior demographics, high-quality graduates, intellectual talent and job growth.  The strategic markets HTA invests in support a strong, long-term demand for quality medical office space.  HTA utilizes an integrated asset management platform consisting of on-site leasing, property management, engineering and building services, and development capabilities to create complete, state of the art facilities in each market.  This drives efficiencies, strong tenant and health system relationships, and strategic partnerships that result in high levels of tenant retention, rental growth and long-term value creation.  Headquartered in Scottsdale, Arizona, HTA has developed a national brand with dedicated relationships at the local level.

Founded in 2006 and listed on the New York Stock Exchange in 2012, HTA has produced attractive returns for its stockholders that have outperformed the US REIT index. More information about HTA can be found on the Company’s Website, Facebook, LinkedIn and Twitter.

Forward-Looking Language
This press release contains certain forward-looking statements.  Forward-looking statements are based on current expectations, plans, estimates, assumptions and beliefs, including expectations, plans, estimates, assumptions and beliefs about HTA, stockholder value and earnings growth.

The forward-looking statements included in this press release are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements.  Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond HTA’s control.  Although HTA believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, HTA’s actual results and performance could differ materially and in adverse ways from those set forth in the forward-looking statements.  Factors which could have a material adverse effect on HTA’s operations and future prospects include, but are not limited to:

  • the Company’s ability to effectively deploy proceeds of offerings of securities;
  • changes in economic conditions affecting the healthcare property sector, the commercial real estate market and the credit market;
  • competition for acquisition and development of medical office buildings and other facilities that serve the healthcare industry;
  • the Company’s ability to acquire or develop real properties, and to successfully operate those properties once acquired or developed;
  • pandemics and other health concerns, and the measures intended to prevent their spread, including the currently ongoing COVID-19 pandemic;
  • economic fluctuations in certain states in which the Company’s investments are geographically concentrated;
  • financial stability and solvency of the Company’s tenants, including the ability and willingness of the Company’s tenants or borrowers to satisfy obligations under their respective contractual arrangements with the Company and the potential inability of the Company to enforce its rights under its leases during the pendency of any pandemic;
  • the ability and willingness of the Company’s tenants to renew their leases with the Company upon expiration of the leases or the Company’s ability to reposition its properties on the same or better terms in the event of a nonrenewal or in the event the Company exercises its right to replace an existing tenant;
  • fluctuations in reimbursements from third party payors such as Medicare and Medicaid;
  • supply and demand for operating properties in the market areas in which the Company operates;
  • changes in operating expenses of the Company’s properties including, but not limited to, expenditures for property taxes, property and liability insurance premiums, and utility rates;
  • the Company’s ability and the ability of its tenants to obtain and maintain adequate property, liability and other insurance from reputable, financial stable providers;
  • restrictive covenants on certain of the Company’s properties subject to ground leases that may restrict or limit the uses of its properties and the types of tenants the Company is able to lease to, and the Company’s ability to attract new tenants;
  • the impact from damage to the Company’s properties from, or increased operating costs associated with, catastrophic weather and other natural events and the physical effect of climate change;
  • retention of the Company’s senior management team and its ability to attract and retain qualified key personnel;
  • legislative and regulatory changes, including changes to laws governing the taxation of real estate investment trusts (“REITs”) and changes to laws governing the healthcare industry;
  • changes in interest rates, including changes a as result of the potential phasing out of the London Inter-bank Offered Rate (“LIBOR”);
  • the availability of capital and financing;
  • restrictive covenants in the Company’s credit facilities;
  • changes in the Company’s credit ratings;
  • HTA’s ability to remain qualified as a REIT;
  • changes in accounting principles generally accepted in the United States of America, policies and guidelines applicable to REITs; and
  • the risk factors set forth in HTA’s most recent Annual Report on Form 10-K and in HTA’s most recent Quarterly Reports on Form 10-Q.

Forward-looking statements speak only as of the date made.  Except as otherwise required by the federal securities laws, HTA undertakes no obligation to update any forward-looking statements to reflect the events or circumstances arising after the date as of which they are made.  As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on the forward-looking statements included in this press release or that may be made elsewhere from time to time by, or on behalf of, HTA.

Financial Contact: 
Robert Milligan
Chief Financial Officer
Healthcare Trust of America, Inc.
480.998.3478
[email protected]    

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/healthcare-trust-of-america-inc-sets-dates-to-report-2020-fourth-quarter-financial-results-and-host-conference-call-301221593.html

SOURCE Healthcare Trust of America, Inc.

JFU DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against 9F Inc.– JFU

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) — Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of 9F Inc. (NASDAQ: JFU) from August 14, 2019 through September 29, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for 9F investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: the purported value and benefits of the Company’s financial institution partners and its tri-party cooperation business model did not in fact exist and/or were materially overstated, given that 9F and Property and Casualty Company Limited (“PICC”) had been engaged in an ongoing contractual dispute regarding payment of service fees under the Cooperation Agreement; the collectability of service fees owed to 9F by PICC under the Cooperation Agreement was in doubt and at serious risk of non-payment; there was a significant risk that PICC would no longer provide credit insurance and guarantee protection to investors and institutional funding partners; as a result of the foregoing, the Company’s platform, business model, reputation and financial results had been materially impaired; and as a result, defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]